Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors.
Constitutive activity of the beta(2)-adrenoceptor, which is sensitive to inhibition by an inverse agonist such as ICI 118551, has been readily demonstrated in recombinant systems expressing constitutively-active mutant receptors or over-expressing the wild-type beta(2)-adrenoceptor. Here we demonstrate the presence of constitutive beta(2)-adrenoceptor activity in BC3H1 cells which endogenously express this receptor. In BC3H1 cells, only ICI 118551 behaved as an inverse agonist at beta(2)-adrenoceptors, while propranolol, ICI 118551, atenolol and, to a lesser extent, alprenolol exhibited inverse agonism in CHO-beta(2)4 cells transfected with cDNA for the human beta(2)-adrenoceptor (310 fmol. mg protein(-1)). The level of expression of beta2-adrenoceptors in BC3H1 cells was not high (78 fmol.mg protein-1) and the efficiency of receptor - effector coupling in this cell line was much lower than in the recombinant CHO-beta(2)4 cells (as judged by the partial agonist nature of both salbutamol and clenbuterol). ICI 118551 (log K(D)-9.73+/-0.07) and propranolol (log K(D)-9.25+/-0.12) both behaved as conventional competitive antagonists of isoprenaline-stimulated cyclic AMP accumulation in high expressing CHO-beta(2)4 cells. In contrast, ICI 118551 appeared to act as a non-competitive antagonist in BC3H1 cells and in low expressing CHO-beta(2)6 cells (50 fmol.mg protein(-1)). This non-competitive effect of ICI 118551 in BC3H1 cells was also observed when either salbutamol was used as agonist, or the incubation period with isoprenaline was extended to 30 min. The possibility that these effects of ICI 118551 are due to an interaction with different affinity states (R, R* and R') of the receptor is discussed.
Hopkinson
H E
HE
Institute of Cell Signalling, Queen's Medical Centre, Nottingham NG7 2UH. School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH.
Latif
M L
ML
Hill
S J
SJ
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism*; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology*; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology*
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D018343:Receptors, Adrenergic, beta-2; C026777:ICI 118551; D000242:Cyclic AMP; D007545:Isoproterenol